Cargando…

Sulforaphane attenuates EGFR signaling in NSCLC cells

BACKGROUND: EGFR, a receptor tyrosine kinase (RTK), is frequently overexpressed and mutated in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have been widely used in the treatment of many cancers, including NSCLC. However, intrinsic and acquired resistance to TKI remains a co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chi-Yuan, Yu, Zhu-Yun, Chuang, Yen-Shu, Huang, Rui-Mei, Wang, Tzu-Chien V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451877/ https://www.ncbi.nlm.nih.gov/pubmed/26036303 http://dx.doi.org/10.1186/s12929-015-0139-x

Ejemplares similares

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
por: Cheong, Hio Teng, et al.
Publicado: (2018)

Sulforaphane Attenuates Isoproterenol-Induced Myocardial Injury in Mice
por: Song, Lijuan, et al.
Publicado: (2020)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
por: Kyung, Sun Young, et al.
Publicado: (2018)

Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC: A case report
por: Wu, Yuan-Peng, et al.
Publicado: (2019)

Sulforaphane Attenuates Gentamicin-Induced Nephrotoxicity: Role of Mitochondrial Protection
por: Negrette-Guzmán, Mario, et al.
Publicado: (2013)

Chemopreventive activity of sulforaphane
por: Jiang, Xin, et al.
Publicado: (2018)

Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors
por: Huang, Chien-Chang, et al.
Publicado: (2016)

Sulforaphane Attenuates Endometriosis in Rat Models Through Inhibiting PI3K/Akt Signaling Pathway
por: Zhou, Aixiu, et al.
Publicado: (2019)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Investigating the Potential for Sulforaphane to Attenuate Gastrointestinal Dysfunction in mdx Dystrophic Mice
por: Swiderski, Kristy, et al.
Publicado: (2021)

Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC
por: Che, Ting-Fang, et al.
Publicado: (2015)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Sulforaphane salads
por: Tiwari, Ashok Kumar
Publicado: (2018)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
por: Chen, Chia-Hung, et al.
Publicado: (2021)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Arasada, Rajeswara Rao, et al.
Publicado: (2018)

USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells
por: McCann, Aidan P., et al.
Publicado: (2018)

Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis
por: Zhang, Xinji, et al.
Publicado: (2012)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

N‐glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC
por: Han, Chia‐Li, et al.
Publicado: (2021)

Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression
por: Wang, Jie, et al.
Publicado: (2021)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Factors Influencing Sulforaphane Content in Broccoli Sprouts and Subsequent Sulforaphane Extraction
por: Tříska, Jan, et al.
Publicado: (2021)

Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH
por: Swiatnicki, Matthew R., et al.
Publicado: (2022)

An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
por: Sun, Li, et al.
Publicado: (2021)

Sulforaphane alleviates psoriasis by enhancing antioxidant defense through KEAP1-NRF2 Pathway activation and attenuating inflammatory signaling
por: Ma, Chujun, et al.
Publicado: (2023)

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth
por: Niu, Mengmeng, et al.
Publicado: (2021)

Comparison of Pharmacokinetics and Anti-Pulmonary Fibrosis-Related Effects of Sulforaphane and Sulforaphane N-acetylcysteine
por: Son, Eun Suk, et al.
Publicado: (2021)

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
por: Wang, Xiaomeng, et al.
Publicado: (2019)

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
por: Huang, Chu-Ying, et al.
Publicado: (2015)

miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway
por: Liu, Yi-Nan, et al.
Publicado: (2020)

Profiling of subcellular EGFR interactome reveals hnRNP A3 modulates nuclear EGFR localization
por: Wang, Tong-Hong, et al.
Publicado: (2020)

Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC
por: Cheng, Fang-Ju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mbtkb522fjhrb83vkap6ie2opm